摘要
目的在新型冠状病毒肺炎患者没有特效药可用的背景下,为完善我国同情用药制度提供国外可借鉴的经验。方法通过文献研究等方法对加拿大特别准入计划的具体内容进行研究。结果加拿大具有相对完善的制度体系,值得我国借鉴。结论结合我国具体国情,从医师、政府、企业3个维度进行同情用药制度的完善。
OBJECTIVE To provide foreign experience for the improvement of China’s compassionate use system under the background that there is no specific medicine for patients with COVID-19. METHODS Studied the specific content of Canada’s special access program through literature research methods and so on. RESULTS Canada has a relatively perfect system, which was worthy of our country’s reference. CONCLUSION According to the specific national conditions of our country, compassionate use system should be improved from three dimensions: doctor, government and drug manufacturer.
作者
任磊
葛其南
舒丽芯
REN Lei;GE Qinan;SHU Lixin(Demonstration Center of Military Medical Supply,School of Pharmacy,Naval Medical University,Shanghai 200433,China;Department of Military Medical Supply Administration,School of Pharmacy,Naval Medical University,Shanghai 200433,China;Shanghai Pharmaceutical Association,Shanghai 200040,China)
出处
《中国现代应用药学》
CAS
CSCD
北大核心
2020年第6期659-663,共5页
Chinese Journal of Modern Applied Pharmacy
基金
后勤科研课题(BWS13B099)
后勤科研重点课题(BWS17J020)。
关键词
加拿大
特别准入计划
同情用药制度
新型冠状病毒肺炎
拓展性用药
Canada
special access program
compassionate use system
COVID-19
expanded access to investigational drug
